{ "id": "S19", "slug": "chronic-disease-advance", "title": "Affordable preventive treatments reduce chronic illness", "version": "0.5.0", "status": "active", "orientation": "upside", "family": "E", "short_title": "Chronic disease advance", "thematics": [ "demographics-human-capital", "economic-security-supply-chains", "ai-cyber-digital" ], "likelihood_type": "systemic", "likelihood_note": "Likelihood is that of the full event: trial confirmation of the effect and licensing that makes treatment affordable in most regions within two years of the results.", "scores": { "likelihood_2y": { "band": 3, "rationale": "The components exist. The SELECT trial showed a 20 per cent reduction in major cardiovascular events from one medicine in 2023 and polypill trials reported 24 and 34 per cent. Generic semaglutide launched in India in March 2026. The full event also needs confirmatory trials of a low-cost combination and licences covering most regions. Trials of that size rarely report and license within two years, which holds the rating at Possible." }, "likelihood_10y": { "band": 4, "rationale": "Over ten years the main patents on current metabolic medicines lapse in most large markets and outcome trials now in progress report. The precedent from statins, antiretrovirals and hepatitis C antivirals is that effective medicines become cheap within a decade of proof. The uncertain part is a combined effect of 30 per cent with selection by biomarkers, which keeps the rating at Likely and not higher." }, "impact_systemic": { "level": 3, "rationale": "Cardiovascular disease caused about 17.9 million deaths in 2019 on World Health Organization estimates, and more than 500 million adults live with diabetes on International Diabetes Federation estimates. A 30 per cent reduction in complications among treated patients, with 15 per cent fewer avoidable admissions and higher working-age participation, shifts health and labour capability in many nations. The output effect builds slowly and is partly offset by pension costs: Significant, not Major." }, "impact_national": { "level": 4, "rationale": "Scored on human welfare and essential services, the highest dimensions reached. In a highly exposed nation with a heavy cardiometabolic burden and working primary care, heart attacks, strokes, kidney failure and amputations fall by close to a third among treated patients and hospital demand is restructured. Pension and care assumptions are reset. The change is Major but leaves the structure of the economy intact." }, "confidence": { "level": "low", "reason": "Trial evidence supports the effect size, but adherence, uptake and the speed of licensing are uncertain. One panel member rated two-year likelihood a band lower and systemic impact a level higher." }, "priority": 12, "tier": "II", "source": "model-panel-v0.5" }, "scorecard": { "onset": "months", "duration": "5 years", "warning": "months", "scope": "global", "origin": "accidental (scientific and commercial)", "external_support": "partial", "policy_response": "current plans executed", "recovery_horizon": "structural" }, "summary": "Large trials establish that a low-cost combination of metabolic treatments and biomarker-guided prevention reduces major cardiovascular and diabetes complications by 30 per cent among eligible patients. Broad licensing and regional production make treatment affordable in most nations within two years. Health systems that adopt it reduce avoidable hospital admissions by 15 per cent over five years and raise working-age participation. To capture the gain a nation must identify eligible patients, sustain primary care and change payment incentives. Longer healthy lives alter pension and workforce assumptions. Providers that depend on treating preventable complications lose revenue, and populations that primary care does not reach fall further behind.", "distribution": { "gains": [ "People with or at high risk of cardiovascular disease, type 2 diabetes and kidney disease", "Health systems with strong primary care and patient registers", "Employers and public finances, through fewer absences and higher working-age participation", "Generic and regional medicines manufacturers holding licences", "Unpaid carers, most of them women, released from caring for relatives with complications" ], "loses": [ "Hospitals and specialist providers paid by the admission or procedure for preventable complications", "Dialysis operators and suppliers of devices and medicines for late-stage disease", "Originator firms whose branded metabolic medicines lose pricing power", "Pension funds, annuity providers and ageing states that priced on shorter lives", "Populations without access to primary care, who fall further behind" ] }, "narrative": { "dateline": "November 2034", "text": "The two trials reported within six weeks of each other in the spring of 2028. Together they had followed 64,000 adults in 29 countries for four years. Patients selected by a short panel of blood and urine markers and given a daily combination of off-patent and newly licensed metabolic medicines had 30 per cent fewer heart attacks, strokes, cases of kidney failure and amputations than those given usual care. The effect held across income groups and in both sexes.\n\nThe price mattered as much as the result. The rights holders agreed non-exclusive licences covering 140 countries before the end of 2028. By early 2030 manufacturers in India, China, Brazil, Egypt and South Africa were supplying the combination at under US$6 a month. The marker panel ran on equipment that most district laboratories already had.\n\nWhat followed divided nations by their health systems more than by their income. Where primary care held a register of patients and was paid for keeping them well, eligible adults were called in, tested and started on treatment within months. Community health workers and pharmacists did most of the monitoring, supported by decision software. In those systems avoidable admissions for cardiovascular and diabetic complications were 15 per cent lower in 2034 than in 2029, and disability claims among people aged 50 to 64 had fallen. More women were in paid work, in part because fewer were caring for a relative after a stroke.\n\nWhere hospitals were paid by the admission and primary care was thin, the medicines reached pharmacies and went little further. Uptake followed the ability to pay for a consultation. Several middle-income nations recorded a widening gap in cardiovascular deaths between cities and rural districts, and between insured and uninsured workers.\n\nThe fiscal effects arrived in a different order from the health effects. Finance ministries booked lower hospital spending slowly, because beds that emptied were filled from waiting lists. Actuaries moved faster. Mortality tables revised in 2032 added about a year to projected life expectancy at 60 in adopting nations, and pension schemes that had assumed otherwise reported larger deficits. Four governments brought forward legislation on pension age. Dialysis operators and cardiac surgery centres closed capacity, and two listed hospital groups restructured their debt.\n\nBy late 2034 the question put to health ministers had changed. It was no longer whether the treatment worked or what it cost. It was why a neighbouring nation with a lower income had cut its stroke admissions by a fifth while their own had not moved." }, "anchors": [ { "shock_id": "glp-1-medicines-2021", "date": "2021–2026", "event": "GLP-1 medicines", "what_happened": "Demand outran supply for several years at prices beyond most health budgets. The SELECT trial, reported in 2023, found that semaglutide reduced major cardiovascular events by 20 per cent among 17,604 adults with overweight or obesity and established cardiovascular disease. Generic semaglutide launched in India in March 2026.", "calibrates": "One metabolic medicine has already delivered two thirds of the assumed effect. Price and supply, not efficacy, held back scale." }, { "shock_id": "scandinavian-simvastatin-survival-study-1994", "date": "1994", "event": "Scandinavian Simvastatin Survival Study", "what_happened": "A trial of 4,444 patients with coronary heart disease found that simvastatin reduced deaths from all causes by 30 per cent over a median of 5.4 years. Statins later lost patent protection and became some of the most widely prescribed medicines in the world.", "calibrates": "An effect of 30 per cent from a medicine that became cheap has a precedent. Population uptake took about two decades, not two years." }, { "shock_id": "cardiovascular-polypill-trials-2019", "date": "2019–2023", "event": "Cardiovascular polypill trials", "what_happened": "The PolyIran trial of 6,838 adults found in 2019 that a four-drug polypill reduced major cardiovascular events by 34 per cent over five years. The SECURE trial of 2,499 patients after a heart attack found a 24 per cent reduction in 2022. The World Health Organization added polypills to its Model List of Essential Medicines in 2023.", "calibrates": "The assumed effect sits inside trial results for low-cost combinations. Use stayed low after the trials: evidence alone does not produce adoption." }, { "shock_id": "egypt-hepatitis-c-campaign-2018", "date": "2018–2023", "event": "Egypt hepatitis C screening and treatment campaign", "what_happened": "Egypt screened about 50 million adults in seven months from October 2018 and treated about four million people with locally made generic antivirals, at a small fraction of the US launch price of US$84,000 a course. The World Health Organization confirmed in 2023 that Egypt had reached gold tier status on the path to elimination.", "calibrates": "Licensing, local production and mass identification of patients can be completed inside two years by a middle-income state that organises for it." }, { "shock_id": "combination-antiretroviral-therapy-1996", "date": "1996 onward", "event": "Combination antiretroviral therapy", "what_happened": "Combination therapy turned HIV from a fatal condition into a chronic one in high-income nations from 1996. Originator prices stood above US$10,000 per patient per year until an Indian generic manufacturer offered triple therapy at US$350 in 2001. Access in Africa lagged by about a decade.", "calibrates": "The access gap between nations when licensing and regional production come late. The scenario assumes that gap closes within two years." }, { "shock_id": "who-global-report-on-hypertension-2023", "date": "September 2023", "event": "WHO global report on hypertension", "what_happened": "The World Health Organization's first global report on hypertension estimated that about 1.3 billion adults had the condition, that nearly half did not know it and that about one in five had it under control, although effective generic medicines cost little.", "calibrates": "Counter-anchor. Cheap and effective prevention already exists and is not delivered. Identification and primary care, not the medicine, set the size of the gain." } ], "parameters": { "common": { "severity": { "major": "major", "severe": "severe", "extreme": "extreme" }, "duration": { "major": "3 years", "severe": "5 years", "extreme": "5 years" }, "onset": { "major": "years", "severe": "months", "extreme": "months" }, "warning": { "major": null, "severe": "months", "extreme": null }, "scope": { "major": "regional", "severe": "global", "extreme": "global" }, "origin": { "major": null, "severe": "accidental (scientific and commercial)", "extreme": null }, "external_support": { "major": "none", "severe": "partial", "extreme": "full" }, "concurrency": { "major": null, "severe": "standalone", "extreme": null }, "policy_response": { "major": null, "severe": "current plans executed", "extreme": "best practice" }, "recovery_horizon": { "major": null, "severe": "structural", "extreme": null } }, "specific": [ { "name": "Reduction in major cardiovascular and diabetes complications among eligible treated patients", "default": "30 per cent", "range": "15 to 40", "unit": "per cent", "note": "Relative to usual care, as established by the trials." }, { "name": "Time from trial results to affordable supply in most nations", "default": "2 years", "range": "1 to 6", "unit": "years", "note": "Set by licence terms, regulatory approval and regional production." }, { "name": "Monthly cost of treatment per patient in licensed markets", "default": "US$6", "range": "US$3 to US$30", "unit": "US$ per month", "note": "Medicines and marker testing. Excludes the cost of consultations." }, { "name": "Share of eligible adults identified and on treatment after five years in adopting systems", "default": "60 per cent", "range": "20 to 80", "unit": "per cent", "note": "The main determinant of the national gain. Set by registers, primary care staffing and payment." }, { "name": "Reduction in avoidable hospital admissions in adopting systems over five years", "default": "15 per cent", "range": "5 to 25", "unit": "per cent", "note": null }, { "name": "Share of adults aged 40 and over who are eligible", "default": "25 per cent", "range": "15 to 40", "unit": "per cent", "note": "Depends on the marker thresholds that regulators adopt." }, { "name": "Gain in projected life expectancy at 60 in adopting nations after five years", "default": "1 year", "range": "0.5 to 2", "unit": "years", "note": "Drives the revision of pension, annuity and long-term care liabilities." } ] }, "transmission": [ "Large trials confirm that the combination, given to patients selected by biomarkers, reduces major cardiovascular and diabetes complications by 30 per cent.", "Rights holders grant broad non-exclusive licences. Regional manufacturers enter and the monthly cost falls to a level that public programmes and households can pay.", "Health systems with patient registers and funded primary care identify eligible adults and start treatment. In systems without them, uptake follows the ability to pay.", "Heart attacks, strokes, kidney failure and amputations fall among treated patients. Avoidable admissions fall 15 per cent over five years in adopting systems.", "Fewer people leave work through illness or to give care. Working-age participation and employment-linked revenue rise.", "Hospitals, dialysis operators and suppliers paid for treating complications lose volume. Payment systems that reward admissions slow the shift of budgets to prevention.", "Mortality assumptions are revised. Pension, annuity and long-term care liabilities rise and governments reopen pension age and contribution rules.", "Differences in outcomes between and within nations widen and become a measure of government performance." ], "loading": [ { "dimension": "Hard", "domain": "defence-security", "load": "Low", "channel": "fitter recruitment pool and fewer medical discharges; no direct effect on force structure" }, { "dimension": "Hard", "domain": "strategic-infrastructure", "load": "Medium", "channel": "primary care sites, laboratories and medicine distribution carry the roll-out; hospital capacity is repurposed" }, { "dimension": "Hard", "domain": "critical-technology", "load": "High", "channel": "medicines manufacturing, biomarker diagnostics, clinical decision software and regulatory science" }, { "dimension": "Soft", "domain": "government-effectiveness", "load": "High", "channel": "licence terms, procurement, patient registers and payment reform decide whether the gain is captured" }, { "dimension": "Soft", "domain": "human-capital", "load": "High", "channel": "healthy life years, working-age participation and the supply of primary care staff" }, { "dimension": "Soft", "domain": "influence-cohesion", "load": "Medium", "channel": "unequal access within nations; licence terms and supply become instruments of health diplomacy" }, { "dimension": "Economic", "domain": "macro-financial", "load": "High", "channel": "lower acute care costs and higher labour supply against larger pension and long-term care liabilities" }, { "dimension": "Economic", "domain": "industry-trade-supply", "load": "Medium", "channel": "generic and regional producers gain; branded metabolic medicines and complication-treatment industries contract" }, { "dimension": "Economic", "domain": "energy-resources", "load": "Low", "channel": "modest change in food demand where appetite-reducing treatments are widely used" } ], "stakeholders": { "government": { "exposure": "Health budgets, payment systems, pension rules and the capacity of primary care to find and follow eligible patients", "actions": [ "Secure licences, regulatory approval and supply early, through pooled procurement where the national market is small", "Fund patient registers and pay primary care for patients kept well, not for admissions", "Re-test pension, disability and long-term care projections on revised mortality assumptions" ], "watch": [ "Share of eligible adults identified and on treatment, by district and income group", "Avoidable admissions for diabetes and heart failure", "Licence coverage and the lowest tender price achieved" ], "relevance": 3 }, "technology": { "exposure": "Medicines manufacturers, diagnostics makers and suppliers of clinical decision and monitoring software", "actions": [ "Qualify regional production and marker testing to regulatory standard ahead of demand", "Build decision support that works in clinics with few staff and intermittent connectivity", "Keep exchange of patient data consent-based and auditable" ], "watch": [ "Regulatory approvals of generic combinations and marker panels", "Supply of active pharmaceutical ingredients", "Adherence rates recorded in monitoring systems" ], "relevance": 4 }, "investors": { "exposure": "Pension funds, annuity writers and health insurers repricing longevity and claims; hospital, dialysis and branded medicine revenues in decline; generic producers and primary care operators growing", "actions": [ "Test pension and annuity books against faster mortality improvement at ages 50 to 80", "Review holdings whose revenue depends on admissions and procedures for preventable complications", "Assess sovereign exposure to age-related spending under longer lives" ], "watch": [ "Mortality tables and the pricing of longevity risk transfers", "Licence terms and patent expiry dates", "Payment reform from fee-for-service to capitation or payment for outcomes" ], "relevance": 4 }, "public": { "exposure": "Access to testing and treatment through primary care; longer working lives and later pensions; fewer households providing care after a stroke or amputation", "actions": [ "Take up testing where it is offered and ask which eligibility thresholds apply", "Hold local health services to published uptake and outcome figures", "Plan household finances for a longer working life" ], "watch": [ "Coverage and co-payment decisions", "Pension age proposals", "Differences in uptake between districts and income groups" ], "relevance": 4 } }, "regions": [ { "region": "north-america", "exposure": "High", "rationale": "High obesity and diabetes prevalence and payment by the procedure: a large health gain and a large loss of provider revenue." }, { "region": "europe", "exposure": "High", "rationale": "Strong primary care in many states supports capture; ageing populations make the pension revision large." }, { "region": "china", "exposure": "High", "rationale": "Very large diabetic and hypertensive population, domestic manufacturing and rapid ageing; hospital-centred care has to change." }, { "region": "indo-pacific", "exposure": "High", "rationale": "Japan and Korea face the sharpest longevity pressure; South-East Asian and Pacific states have rising diabetes and uneven primary care." }, { "region": "south-asia", "exposure": "High", "rationale": "Diabetes and heart disease strike early in working life; the generic manufacturing base supplies other regions." }, { "region": "gulf-middle-east", "exposure": "High", "rationale": "Diabetes prevalence is some of the highest in the world; the means to pay exist but care is hospital-centred." }, { "region": "africa", "exposure": "Medium", "rationale": "The burden is rising from a lower base in young populations; thin primary care and diagnostics limit capture." }, { "region": "latin-america", "exposure": "High", "rationale": "High obesity and diabetes, notably in Mexico; segmented health coverage decides who is reached." }, { "region": "russia-eurasia", "exposure": "High", "rationale": "High cardiovascular mortality among working-age men gives a large potential gain; primary care and access are weak." } ], "indicators": [ { "name": "Results of cardiovascular and kidney outcome trials of oral and combination metabolic medicines", "source": "ClinicalTrials.gov; The New England Journal of Medicine; The Lancet", "threshold": "Two independent trials reporting a reduction of 25 per cent or more in major events", "cadence": "As published" }, { "name": "Voluntary licences for metabolic medicines and the countries they cover", "source": "Medicines Patent Pool; company licensing announcements", "threshold": "Non-exclusive licences covering more than 100 countries", "cadence": "As announced" }, { "name": "Lowest monthly price of generic GLP-1 and SGLT2 medicines by country", "source": "PAHO Strategic Fund reference prices; national tender results", "threshold": "Below US$10 a month in most middle-income markets", "cadence": "Annual" }, { "name": "Regulatory approvals of generic and combination metabolic medicines from regional producers", "source": "National regulators, including CDSCO in India, ANVISA in Brazil and SAHPRA in South Africa", "threshold": null, "cadence": "As published" }, { "name": "Listing of combination and metabolic medicines as essential medicines", "source": "WHO Model List of Essential Medicines", "threshold": "Listing of the combination for primary prevention", "cadence": "Every two years" }, { "name": "Share of adults with hypertension and diabetes who are diagnosed, treated and controlled", "source": "WHO Global Health Observatory; NCD Risk Factor Collaboration", "threshold": "Control above 50 per cent of those with the condition", "cadence": "Periodic" }, { "name": "Avoidable hospital admissions for diabetes and congestive heart failure", "source": "OECD Health Statistics", "threshold": "A fall of more than 5 per cent in two years in an adopting system", "cadence": "Annual" }, { "name": "Life expectancy at 60 and the mortality assumptions used by pension schemes", "source": "UN World Population Prospects; Human Mortality Database", "threshold": "Upward revision of half a year or more between editions", "cadence": "Every two years" } ], "compounds": { "triggers": [ { "id": "S20", "note": "licensing practice, regulatory reliance and regional medicines production built here raise readiness for a distributed outbreak response" }, { "id": "S02", "note": "longevity revisions add to the pension liabilities of ageing sovereigns; a contributing pressure, not a cause alone" } ], "triggered_by": [ { "id": "S17", "note": "AI-directed research shortens the development of the combination and of the marker panel" }, { "id": "S18", "note": "identity and consent-based data exchange make patient registers and recall workable at national scale" }, { "id": "S11", "note": "released fiscal capacity lets indebted states fund primary care and procurement" }, { "id": "S20", "note": "Regional production, broad licensing and primary care delivery proven in the outbreak carry over to preventive treatments." } ], "amplified_by": [ { "id": "S08", "note": "the same low-cost AI agents support monitoring and recall where health workers are scarce" } ], "triggered_by_other": [ "Patent expiry of leading metabolic medicines in major markets", "A pooled procurement decision by several large public purchasers" ], "amplifying_trends": [ "Biomarker-guided precision medicine", "AI drug development", "Chronic disease & obesity burden", "Digital & AI-supported care", "Healthy lifespan divergence", "Health workforce scarcity", "Regional medicines manufacturing", "Age-related fiscal liabilities" ] }, "open_questions": [ "Whether an onset of months is right. Trial results and licences arrive within months, but the 15 per cent fall in admissions takes five years: the record may describe a shock followed by a trend.", "How to score a nation where the treatment is licensed and affordable but primary care cannot identify or follow patients: as failing to gain, or as losing ground to its neighbours.", "Whether longer healthy lives count as a load on macro-financial capability or a gain to it, given that pension liabilities and labour supply both rise.", "Africa is rated Medium on present burden and age structure. That may understate exposure where diabetes and hypertension are rising fastest and are mostly undiagnosed." ], "commentary": null, "overview": { "source": "model-panel-v0.5", "lenses": { "political": "Health ministers are judged against neighbours: they are asked **why outcomes differ when the price does not**. Pension age returns to the legislature.", "economic": "Admissions fall and participation rises, but **pension and annuity liabilities are revised up** and providers paid for treating complications lose revenue.", "social": "Treated patients have 30 per cent fewer major complications. **Uptake follows access to primary care**, so gaps within nations widen where care is thin.", "technological": "The advance is a combination of known and new medicines **guided by a low-cost marker panel**, supported by decision software and made by regional producers.", "legal": "**Broad non-exclusive licences** set the price. Regulators must approve the combination, fix eligibility thresholds and permit pharmacists and health workers to monitor patients.", "environmental": "Environmental effects are small. **Food demand shifts modestly** where appetite-reducing treatments are widely used, and new production sites add pharmaceutical effluent to control." }, "regions": { "north-america": "High obesity and diabetes give a large health gain. **Providers paid by the procedure** lose revenue and resist payment reform.", "europe": "Strong primary care in many states supports capture. Ageing populations make the **pension revision large**.", "china": "A very large diabetic and hypertensive population and domestic manufacturing. **Hospital-centred care has to change** as the population ages quickly.", "indo-pacific": "Japan and Korea face the **sharpest longevity pressure**. South-East Asian and Pacific states have rising diabetes and uneven primary care.", "south-asia": "Diabetes and heart disease **strike early in working life**, so the labour gain is large. The generic manufacturing base supplies other regions.", "gulf-middle-east": "Diabetes prevalence is some of the highest in the world. The means to pay exist, but **care is hospital-centred**.", "africa": "The burden is rising from a lower base in young populations. **Thin primary care and diagnostics** limit how much of the gain is captured.", "latin-america": "High obesity and diabetes, notably in Mexico. **Segmented health coverage** decides who is reached and who is not.", "russia-eurasia": "High cardiovascular mortality among **working-age men** gives a large potential gain. Weak primary care and constrained access hold it back." }, "evolution": { "lead_indicators": "**Two independent trials** report major events cut by 25 per cent or more. Non-exclusive licences cover more than 100 countries and generic prices fall below US$10 a month.", "triggers": "Two trials following 64,000 adults in 29 countries show **30 per cent fewer** heart attacks, strokes, cases of kidney failure and amputations among biomarker-selected patients on a low-cost combination.", "immediate": "Rights holders agree non-exclusive licences covering 140 countries within months. Within two years regional manufacturers supply the combination at **under US$6 a month**.", "post_immediate": "Systems with patient registers and funded primary care start eligible adults on treatment within months. Elsewhere **uptake follows the ability to pay** and gaps within nations widen.", "stabilisation": "Over five years adopting systems cut **avoidable admissions by 15 per cent** and working-age participation rises. Dialysis operators and cardiac surgery centres close capacity; hospital savings arrive slowly.", "long_term": "Revised mortality tables add **about a year to projected life expectancy at 60**. Pension deficits grow, governments legislate on pension age and outcome gaps between nations measure government performance." } }, "history": [ { "edition": 2027, "rank": null, "L2y": 3, "L10y": 4, "impact_systemic": 3, "impact_national": 4, "confidence": "low" } ], "changelog": [ { "version": "0.5.0", "date": "2026-10-09", "change": "Rebuilt in the second pass from Biomedical breakthrough wave: narrowed to low-cost prevention of cardiovascular and metabolic disease, with onset moved from years to months, regional exposure revised and the HIV, malaria and cancer vaccine elements removed." } ], "citation": "GINC (2027). Scenario S19 Affordable preventive treatments reduce chronic illness, Scenario Library v0.5. scenarios.ginc.org/scenarios/chronic-disease-advance" }